Crossmark

Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement

Crossref DOI link: https://doi.org/10.1007/s12350-022-03059-5

Published Print: 2022-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Miller, Edward J.

Campisi, Roxana

Shah, Nishant R.

McMahon, Sean

Cuddy, Sarah

Gallegos-Kattan, Cesia

Maurer, Mathew S.

Damy, Thibaud

Slart, Riemer H.J.A.

Bhatia, Ketan

Einstein, Andrew J.
License Information

Text and Data Mining valid from 2022-10-01

Text and Data Mining valid from 2022-10-01
More Information

This article is maintained by: Elsevier

Article Title: Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement

Journal Title: Journal of Nuclear Cardiology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s12350-022-03059-5

Content Type: article

Copyright: Copyright © 2022 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.

Document is current

Any future updates will be listed below